Human Insulin Market Size, Trends and Insights By Type (Modern Human Insulin, Traditional Human Insulin), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Type of Diabetes (Diabetes Type 1, Diabetes Type 2), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- Novo Nordisk A/S
- Eli Lilly and Company
- Tonghua Dongbao Pharmaceutical Co., Ltd
- Others
Reports Description
The human insulin market presented an earning of USD 44 billion in 2021 and is foreseen to touch USD 70.68 billion by the end of 2030 at a compound annual growth rate of 8%. A rapidly increasing number of cases of diabetes in the world has boosted the demand for the human insulin market tremendously.
The long-term treatment which needs to be taken after diabetes is detected proves to be a major obstacle to the growth of the market during the forecast period. People have opted for advanced human insulin options and natural medicines in order to manage their diabetic profiles with a view to avoiding the associated side effects with the use of modern medicine. The sedentary lifestyle practices are followed by the people working in the corporate sector and businesses suffer from obesity which proves to be a major positive factor for diabetes and boosting the market for human insulin. The dose of human insulin holds great importance as it has a direct impact on the level of blood sugar.
The chances of manual error are more with people belonging to the elderly age group which is taken care of with the help of modern insulin techniques which calculate the amount of dosage to be administered to the individual.
The outbreak of the pandemic had a significant impact on the growth of the market as a result of the restricted moment and constantly locked imposed by the government all over the world. The health conditions of the patients were not evaluated correctly as a result of the covid situation which was created.
The healthcare sector did not attend the regular follow-ups and minor complaints in order to safeguard the resources with a view to treating the covid patients. This had given a tremendous boost to the online pharmacy segment for human insulin which helps people to avail of essential drugs without visiting a healthcare center. Diabetes was also experienced to be a complication of this pandemic which made things worse for the infected patients. The high cost of human insulin and diabetic medicines imposes and additional pressure on the already suffering individual and proves to be a major obstacle to the growth of the market during the forecast period.
Growth Factors
The increasing advancement in technology and extensive research and development carried out by the key market players have helped the health care sector to provide patients with modern human insulin. There rapidly increasing number of patients suffering from diabetes become a major growth factor for the market.
The use number of complications and side effects which are associated with a diabetic patient has also increased the need for modern insulin techniques. Advanced facilities such as online pharmacies which are provided by the key market players have helped the market to record a considerable revenue over the period of time which experienced reminders boost during the period of the pandemic. The increasing number of people belonging to the old age group has helped to boost the market for human insulin.
The rapid awareness regarding the various facilities available in the healthcare sector which are backed by the government has boosted the market for human insulin. Insurance companies have also provided lucrative facilities to such patients which boosts the market for human insulin. The availability of generic drugs which are made for people belonging to the lower economic class helps to boost the market for human insulin. A huge number of patients have emerged in recent times as a result of the increasing stress and consumption of packet food products.
Segmental Insights
Segmentation On the Basis of Type
On the basis of type, the segment of modern human insulin has presented the largest share as a result of the rapid acceptance of advanced technology in the healthcare sector. With the rapidly increasing prevalence of the number of patients suffering with diabetes the need for advanced technology is increasing tremendously which proves to be a great opportunity for the growth of the human insulin market.
The process of administration of advanced human insulin is similar to that of the traditional human insulin with the help of pens or injectors. The advanced technology which is used in modern human insulin controls the diabetes of the individual in a better manner. The rapid number of cases growing all over the world is increasing the need for modern types of insulin which have a better effect on the health of the individual and lead to lesser side effects over the period of time.
The faster action which is received with the help of modern human insulin roast to be a major opportunity for the growth of the market as it is highly useful in the emergency hospitals where the condition of the patient is usually critical and needs quick management in a short repeated of time to stabilize the patient.
The use number of the population belonging to the genetic age group has also boosted the demand for modern insulin products in order to have better management of diabetes. Traditional human insulin will continue to show its growth in the market but with the increasing number of cases, the demand for modern human insulin is foreseen to grow tremendously during the forecast period.
Segmentation on the basis of Distribution Channel
On the basis of distribution channels, the segment of online pharmacies is shown the largest share in the market as a result of its use demand pertaining to the recent trend of online shopping. The facility of online pharmacy proves to be of great comfort to the geriatric population who are dependent on some individual in order to fulfill their demands and needs. This facility helps elderly people to gain complete independence regarding their healthcare needs and demands. It also enables them to go through the huge variety of products in order to select the required features and properties as per their own wish.
During the outbreak of the pandemic, this facility of online pharmacies has proved to be a life-saving method for many individuals and families all over the world. The strict restrictions regarding the movement of the people which were laid by the government in order to control the spread of infection had hampered the purchasing facility of the people which was taken care of by the online pharmacies.
The facility of online pharmacies helps the people residing in the rural areas as well by providing them with essential services at a very minimal delivery charge. As a result of the rapid urbanization, people are busy working in corporate offices for a long period of time which does not allow them to visit healthcare facilities in order to get themselves treated which is taken care of with the help of online form which makes the essential medicines available according to their own comfortable time and location.
The hospital pharmacies have also seen tremendous growth as a result of the huge number of patients who visit the health care sector in order to get themselves checked on a regular basis and to visit for regular follow-ups. The retail pharmacies on the other hand, experience a huge demand and supply as a result of the constant requirement of these medicines in the market. In order to save the additional expense related to the hospital, people prefer to visit retail pharmacies to purchase this medicine.
Segmentation on the basis of the Type of Diabetes
On the basis of the type of diabetes, type 1 diabetes has been seen to be more prevalent among the people residing in the region of North America and the Asia Pacific region. The people residing in the sector of Latin America and England have shown a greater prevalence of type 2 diabetes. Due to the rapid modernization and urbanization of the world, the lifestyle of the people is drastically altered which has led to a number of chronic diseases.
The sedentary lifestyle habits which are practiced by the modern generation have given rise to the occurrence of this chronic disease at a very early age. A huge number of children are also suffering from this disease which proves to be a potential market for human insulin. Anti-diabetic medicines once started are difficult to be discontinued as a result of their habit-creation feature which makes them an ever-growing market. The prevalence of type 1 diabetes is higher as compared to type 2 diabetes which makes it a dominant segment and is foreseen to continue its growth during the future period as well.
Report Scope
| Feature of the Report | Details |
| Market Size in 2021 | USD 44 Billion |
| Projected Market Size in 2030 | USD 70.68 Billion |
| CAGR Growth Rate | 8% CAGR (2022-2030) |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Prominent Players | Novo Nordisk A/S, Eli Lilly and Company, Tonghua Dongbao Pharmaceutical Co., Ltd., ADOCIA, Sanofi, Biocon, Wockhardt, Julphar, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc., Pfizer, Inc., Oramed Pharmaceuticals, Inc., and Others |
| Key Segment | By Type, Distribution Channel, Type of Diabetes, and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Regional Insights
On the basis of geography, the region of North America has proved to be the largest market for human insulin as a result of the huge number of patients who are residing in this part of the world. A huge number of patients belonging to the geriatric age group suffer from this disease as a result of faulty lifestyle practices and obesity.
The increasing consumption of fast food and packaged food products boosted the number of diabetes which proves to be a further complication of obesity. The amount of packed food and sugar which is consumed in this region has increased tremendously which leads to the occurrence of diabetes among people and children. The countries belonging to the Asia Pacific region have also shown a tremendous boost in the size of the market as a result of the huge population suffering from diabetes.
The lifestyle practices which are followed in the series region as a result of modernization have hampered the health of the youngsters. Young people and children are seen to be suffering from diabetes as a result of sedentary lifestyle practices and excessive intake of sugar. Platinum America and Europe have also presented reminders increase in the number of patients suffering from diabetes. Advance health care facilities that are provided to the people by this geographical sector have proved to be a major growth factor for the human insulin market.
Recent Developments
A generic version of Humalog was conducted in the year 2019 in month of April by Eli Lily and the company under the title of Insulin Lispro. The total expense was around half of the current price.
Segments covered under the Human Insulin Market
By Type
- Modern Human Insulin
- Traditional Human Insulin
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Type of Diabetes
- Diabetes Type 1
- Diabetes Type 2
On the basis of Geography
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Human Insulin Market, (2022 – 2030) (USD Billion)
- 2.2 Global Human Insulin Market: snapshot
- Chapter 3. Global Human Insulin Market – Industry Analysis
- 3.1 Human Insulin Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Increasing advancement in technology
- 3.2.2 the Rapidly increasing number of patients suffering from diabetes
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Type
- 3.7.2 Market attractiveness analysis By Distribution Channel
- 3.7.3 Market attractiveness analysis By Type of Diabetes
- Chapter 4. Global Human Insulin Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Human Insulin Market: company market share, 2021
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Human Insulin Market – Type Analysis
- 5.1 Global Human Insulin Market overview: By Type
- 5.1.1 Global Human Insulin Market share, By Type, 2021 and 2030
- 5.2 Modern Human Insulin
- 5.2.1 Global Human Insulin Market by Modern Human Insulin, 2022 – 2030 (USD Billion)
- 5.3 Traditional Human Insulin
- 5.3.1 Global Human Insulin Market by Traditional Human Insulin, 2022 – 2030 (USD Billion)
- 5.1 Global Human Insulin Market overview: By Type
- Chapter 6. Global Human Insulin Market – Distribution Channel Analysis
- 6.1 Global Human Insulin Market overview: By Distribution Channel
- 6.1.1 Global Human Insulin Market share, By Distribution Channel, 2021 and 2030
- 6.2 Retail Pharmacies
- 6.2.1 Global Human Insulin Market by Retail Pharmacies, 2022 – 2030 (USD Billion)
- 6.3 Hospital Pharmacies
- 6.3.1 Global Human Insulin Market by Hospital Pharmacies, 2022 – 2030 (USD Billion)
- 6.4 Online Pharmacies
- 6.4.1 Global Human Insulin Market by Online Pharmacies, 2022 – 2030 (USD Billion)
- 6.1 Global Human Insulin Market overview: By Distribution Channel
- Chapter 7. Global Human Insulin Market – Type of Diabetes Analysis
- 7.1 Global Human Insulin Market overview: By Type of Diabetes
- 7.1.1 Global Human Insulin Market share, By Type of Diabetes, 2021 and 2030
- 7.2 Diabetes Type 1
- 7.2.1 Global Human Insulin Market by Diabetes Type 1, 2022 – 2030 (USD Billion)
- 7.3 Diabetes Type 2
- 7.3.1 Global Human Insulin Market by Diabetes Type 2, 2022 – 2030 (USD Billion)
- 7.1 Global Human Insulin Market overview: By Type of Diabetes
- Chapter 8. Human Insulin Market – Regional Analysis
- 8.1 Global Human Insulin Market Regional Overview
- 8.2 Global Human Insulin Market Share, by Region, 2021 & 2030 (USD Billion)
- 8.3. North America
- 8.3.1 North America Human Insulin Market, 2022 – 2030 (USD Billion)
- 8.3.1.1 North America Human Insulin Market, by Country, 2022 – 2030 (USD Billion)
- 8.3.1 North America Human Insulin Market, 2022 – 2030 (USD Billion)
- 8.4 North America Human Insulin Market, by Type, 2022 – 2030
- 8.4.1 North America Human Insulin Market, by Type, 2022 – 2030 (USD Billion)
- 8.5 North America Human Insulin Market, by Distribution Channel, 2022 – 2030
- 8.5.1 North America Human Insulin Market, by Distribution Channel, 2022 – 2030 (USD Billion)
- 8.6 North America Human Insulin Market, by Type of Diabetes, 2022 – 2030
- 8.6.1 North America Human Insulin Market, by Type of Diabetes, 2022 – 2030 (USD Billion)
- 8.4. Europe
- 8.4.2 Europe Human Insulin Market, 2022 – 2030 (USD Billion)
- 8.4.2.1 Europe Human Insulin Market, by Country, 2022 – 2030 (USD Billion)
- 8.4.2 Europe Human Insulin Market, 2022 – 2030 (USD Billion)
- 8.4 Europe Human Insulin Market, by Type, 2022 – 2030
- 8.4.1 Europe Human Insulin Market, by Type, 2022 – 2030 (USD Billion)
- 8.5 Europe Human Insulin Market, by Distribution Channel, 2022 – 2030
- 8.5.1 Europe Human Insulin Market, by Distribution Channel, 2022 – 2030 (USD Billion)
- 8.6 Europe Human Insulin Market, by Type of Diabetes, 2022 – 2030
- 8.6.1 Europe Human Insulin Market, by Type of Diabetes, 2022 – 2030 (USD Billion)
- 8.5. Asia Pacific
- 8.5.3 Asia Pacific Human Insulin Market, 2022 – 2030 (USD Billion)
- 8.5.3.1 Asia Pacific Human Insulin Market, by Country, 2022 – 2030 (USD Billion)
- 8.5.3 Asia Pacific Human Insulin Market, 2022 – 2030 (USD Billion)
- 8.4 Asia Pacific Human Insulin Market, by Type, 2022 – 2030
- 8.4.1 Asia Pacific Human Insulin Market, by Type, 2022 – 2030 (USD Billion)
- 8.5 Asia Pacific Human Insulin Market, by Distribution Channel, 2022 – 2030
- 8.5.1 Asia Pacific Human Insulin Market, by Distribution Channel, 2022 – 2030 (USD Billion)
- 8.6 Asia Pacific Human Insulin Market, by Type of Diabetes, 2022 – 2030
- 8.6.1 Asia Pacific Human Insulin Market, by Type of Diabetes, 2022 – 2030 (USD Billion)
- 8.6. Latin America
- 8.6.4 Latin America Human Insulin Market, 2022 – 2030 (USD Billion)
- 8.6.4.1 Latin America Human Insulin Market, by Country, 2022 – 2030 (USD Billion)
- 8.6.4 Latin America Human Insulin Market, 2022 – 2030 (USD Billion)
- 8.4 Latin America Human Insulin Market, by Type, 2022 – 2030
- 8.4.1 Latin America Human Insulin Market, by Type, 2022 – 2030 (USD Billion)
- 8.5 Latin America Human Insulin Market, by Distribution Channel, 2022 – 2030
- 8.5.1 Latin America Human Insulin Market, by Distribution Channel, 2022 – 2030 (USD Billion)
- 8.6 Latin America Human Insulin Market, by Type of Diabetes, 2022 – 2030
- 8.6.1 Latin America Human Insulin Market, by Type of Diabetes, 2022 – 2030 (USD Billion)
- 8.7. The Middle-East and Africa
- 8.7.5 The Middle-East and Africa Human Insulin Market, 2022 – 2030 (USD Billion)
- 8.7.5.1 The Middle-East and Africa Human Insulin Market, by Country, 2022 – 2030 (USD Billion)
- 8.7.5 The Middle-East and Africa Human Insulin Market, 2022 – 2030 (USD Billion)
- 8.4 The Middle-East and Africa Human Insulin Market, by Type, 2022 – 2030
- 8.4.1 The Middle-East and Africa Human Insulin Market, by Type, 2022 – 2030 (USD Billion)
- 8.5 The Middle-East and Africa Human Insulin Market, by Distribution Channel, 2022 – 2030
- 8.5.1 The Middle-East and Africa Human Insulin Market, by Distribution Channel, 2022 – 2030 (USD Billion)
- 8.6 The Middle-East and Africa Human Insulin Market, by Type of Diabetes, 2022 – 2030
- 8.6.1 The Middle-East and Africa Human Insulin Market, by Type of Diabetes, 2022 – 2030 (USD Billion)
- Chapter 9. Company Profiles
- 9.1 Novo Nordisk A/S
- 9.1.1 Overview
- 9.1.2 Financials
- 9.1.3 Product Portfolio
- 9.1.4 Business Strategy
- 9.1.5 Recent Developments
- 9.2 Eli Lilly and Company
- 9.2.1 Overview
- 9.2.2 Financials
- 9.2.3 Product Portfolio
- 9.2.4 Business Strategy
- 9.2.5 Recent Developments
- 9.3 Tonghua Dongbao Pharmaceutical Co. Ltd.
- 9.3.1 Overview
- 9.3.2 Financials
- 9.3.3 Product Portfolio
- 9.3.4 Business Strategy
- 9.3.5 Recent Developments
- 9.4 ADOCIA
- 9.4.1 Overview
- 9.4.2 Financials
- 9.4.3 Product Portfolio
- 9.4.4 Business Strategy
- 9.4.5 Recent Developments
- 9.5 Sanofi
- 9.5.1 Overview
- 9.5.2 Financials
- 9.5.3 Product Portfolio
- 9.5.4 Business Strategy
- 9.5.5 Recent Developments
- 9.6 Biocon
- 9.6.1 Overview
- 9.6.2 Financials
- 9.6.3 Product Portfolio
- 9.6.4 Business Strategy
- 9.6.5 Recent Developments
- 9.7 Wockhardt
- 9.7.1 Overview
- 9.7.2 Financials
- 9.7.3 Product Portfolio
- 9.7.4 Business Strategy
- 9.7.5 Recent Developments
- 9.8 Julphar
- 9.8.1 Overview
- 9.8.2 Financials
- 9.8.3 Product Portfolio
- 9.8.4 Business Strategy
- 9.8.5 Recent Developments
- 9.9 Bristol-Myers Squibb Company
- 9.9.1 Overview
- 9.9.2 Financials
- 9.9.3 Product Portfolio
- 9.9.4 Business Strategy
- 9.9.5 Recent Developments
- 9.10 GlaxoSmithKline Plc
- 9.10.1 Overview
- 9.10.2 Financials
- 9.10.3 Product Portfolio
- 9.10.4 Business Strategy
- 9.10.5 Recent Developments
- 9.11 Merck & Co. Inc.
- 9.11.1 Overview
- 9.11.2 Financials
- 9.11.3 Product Portfolio
- 9.11.4 Business Strategy
- 9.11.5 Recent Developments
- 9.12 Pfizer Inc.
- 9.12.1 Overview
- 9.12.2 Financials
- 9.12.3 Product Portfolio
- 9.12.4 Business Strategy
- 9.12.5 Recent Developments
- 9.13 Oramed Pharmaceuticals Inc.
- 9.13.1 Overview
- 9.13.2 Financials
- 9.13.3 Product Portfolio
- 9.13.4 Business Strategy
- 9.13.5 Recent Developments
- 9.1 Novo Nordisk A/S
List Of Figures
Figures No 1 to 23
List Of Tables
Tables No 1 to 77
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2030
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Key Market Players
- Novo Nordisk A/S
- Eli Lilly and Company
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- ADOCIA
- Sanofi
- Biocon
- Wockhardt
- Julphar
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- Pfizer, Inc.
- Oramed Pharmaceuticals, Inc.
- Others
FAQs
North American region will lead the global Human Insulin market during the forecast period 2022 to 2030.
The increasing advancement in technology and extensive research and development carried out by the key market players have helped the health care sector to provide patients with modern human insulin. There rapidly increasing number of patients suffering from diabetes become a major growth factor for the market.
The key players operating in the Human Insulin market are Novo Nordisk A/S, Eli Lilly and Company, Tonghua Dongbao Pharmaceutical Co., Ltd., ADOCIA, Sanofi, Biocon, Wockhardt, Julphar, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc., Pfizer, Inc., Oramed Pharmaceuticals, Inc., and Others.
The global Human Insulin market is expanding growth with a CAGR of approximately 8% during the forecast period (2022 to 2030).
The global Human Insulin market size was valued at USD 44 billion in 2021 and it is projected to reach around USD 70.68 billion by 2030.